Daré Bioscience, Inc. (NASDAQ:DARE) Short Interest Update

Daré Bioscience, Inc. (NASDAQ:DARE) saw a large decline in short interest during the month of February. As of February 28th, there was short interest totalling 71,500 shares, a decline of 21.5% from the February 13th total of 91,100 shares. Currently, 0.8% of the shares of the company are sold short. Based on an average daily volume of 36,300 shares, the short-interest ratio is presently 2.0 days.

Institutional Trading of Daré Bioscience

Hedge funds have recently modified their holdings of the stock. AMH Equity Ltd raised its holdings in Daré Bioscience by 50.0% in the 4th quarter. AMH Equity Ltd now owns 150,000 shares of the biotechnology company’s stock valued at $468,000 after acquiring an additional 50,000 shares during the period. Geode Capital Management LLC increased its stake in shares of Daré Bioscience by 4.0% during the fourth quarter. Geode Capital Management LLC now owns 92,653 shares of the biotechnology company’s stock worth $289,000 after purchasing an additional 3,593 shares during the period. Renaissance Technologies LLC increased its stake in shares of Daré Bioscience by 6.7% during the fourth quarter. Renaissance Technologies LLC now owns 68,695 shares of the biotechnology company’s stock worth $214,000 after purchasing an additional 4,300 shares during the period. Finally, Jane Street Group LLC acquired a new stake in Daré Bioscience during the 4th quarter worth approximately $52,000. Institutional investors and hedge funds own 6.70% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of Daré Bioscience in a research note on Tuesday, December 17th.

Daré Bioscience Stock Performance

DARE traded up $0.09 during trading hours on Tuesday, reaching $2.97. The company’s stock had a trading volume of 11,879 shares, compared to its average volume of 45,958. The company’s 50-day moving average is $3.13 and its 200-day moving average is $3.32. Daré Bioscience has a 52 week low of $2.67 and a 52 week high of $7.56. The firm has a market cap of $25.84 million, a PE ratio of -5.03 and a beta of 1.38.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.